Opus Genetics reports Cohort 1 data for OPGx-BEST1, aligns with FDA on pivotal endpoint
All five patients in the low-dose cohort showed visual function improvement, and Opus plans Phase 3 dosing in 2027 after an August FDA meeting.
SEC filing
Latest
4 stories
Wednesday, September 9
Friday, August 21
Viatris: Ocuphire trial results posted, Amnesteem label update, gabapentin abuse study completed
Monday, August 17
Ocuphire's Phase 3 VEGA-3 presbyopia trial posts results on ClinicalTrials.gov
Thursday, August 6
Opus Genetics reports Q2 2026 results, cites September BEST1 data and LCA5 dosing plan
Cash stood at $88.8 million as of June 30, 2026, with runway guidance into 2029 as multiple retinal gene therapy programs move toward clinic.
SEC filing